The earnings call highlighted several positive developments, including a new patent, additional funding, and significant clinical trial results. Financial results showed improvement with increased cash reserves and reduced expenses. However, challenges such as the reverse stock split and strategic delays in clinical trials were noted. Overall, the sentiment is cautiously optimistic.

Company Guidance

During the Acurx Pharmaceuticals second-quarter 2025 financial results conference call, several key metrics and updates were discussed. The company announced a significant decrease in research and development expenses, down to $0.5 million for the quarter compared to $1.8 million in the same period in 2024, and a reduction in general and administrative expenses to $1.7 million from $2.3 million. A net loss of $2.2 million or $1.89 per diluted share was reported for the quarter, showing an improvement from a net loss of $4.1 million or $5.21 per diluted share the previous year. The call highlighted strategic financial moves, including a $12 million equity line of credit and a warrant inducement agreement, which contributed to raising $3.4 million in gross proceeds. Additional updates included the publication of Phase IIb clinical trial data for ibezapolstat in Lancet Microbe, emphasizing the drug's high rates of clinical cure and potential impact on reducing the $5 billion annual U.S. cost burden for C. difficile infections. The company also implemented a 1-for-20 reverse stock split to comply with NASDAQ requirements, with cash reserves at $6.1 million by the end of the quarter.

New Patent Granted

The Indian Patent Office granted a new patent for DNA polymerase IIIC inhibitors, significant for the ongoing preclinical antibiotic development program.

Equity Line of Credit

Closed an equity line of credit with Lincoln Park Capital for up to $12 million of additional funding.

Phase IIb Clinical Trial Publication

Published in Lancet Microbe, highlighted high clinical cure rates and no recurrence for ibezapolstat in C. difficile infection.

Financial Improvements

Cash increased to $6.1 million from $3.7 million, with a reduction in net loss and operating expenses compared to the previous year.

Cost Reduction

Research and development expenses decreased by $1.3 million, and general and administrative expenses decreased by $0.6 million compared to the previous year.

Acurx Pharmaceuticals (ACXP) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ACXP Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 18, 2025	2025 (Q3)	-1.31 / -	-3.4	―	―	―
Aug 12, 2025	2025 (Q2)	-2.33 / -1.89	-5.2	63.65% (+3.31)	―
May 13, 2025	2025 (Q1)	-2.60 / -2.20	-5.6	60.71% (+3.40)	―
Mar 18, 2025	2024 (Q4)	-3.50 / -3.20	-7.4	56.76% (+4.20)	―
Nov 13, 2024	2024 (Q3)	-2.90 / -3.40	-4.8	29.17% (+1.40)	―
Aug 09, 2024	2024 (Q2)	-3.30 / -5.20	-5.6	7.14% (+0.40)	―
May 15, 2024	2024 (Q1)	-3.00 / -5.60	-5	-12.00% (-0.60)	―
Mar 18, 2024	2023 (Q4)	-4.90 / -7.40	-5.6	-32.14% (-1.80)	―
Nov 14, 2023	2023 (Q3)	-5.40 / -4.80	-6.4	25.00% (+1.60)	―
Aug 14, 2023	2023 (Q2)	-4.67 / -5.60	-5.2	-7.69% (-0.40)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ACXP Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	$4.48	$4.44	-0.89%
May 13, 2025	$7.91	$7.60	-3.92%
Mar 18, 2025	$9.46	$8.12	-14.16%
Nov 13, 2024	$37.00	$36.40	-1.62%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Acurx Pharmaceuticals (ACXP) report earnings?

Acurx Pharmaceuticals (ACXP) is schdueled to report earning on Nov 18, 2025, After Close (Confirmed).

What is Acurx Pharmaceuticals (ACXP) earnings time?

Acurx Pharmaceuticals (ACXP) earnings time is at Nov 18, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ACXP EPS forecast?

ACXP EPS forecast for the fiscal quarter 2025 (Q3) is -1.31.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing